20102020 Apsis Therapeutics, Ltd. All rights reserved.

Our Technologies

bcProtideTM

 

bcProtideTM is a nucleoside analogue prodrug technology developed by APSIS for better efficacies, selective cellular delivery, and low toxicities of metabolizing intermediates and byproducts.

 

 

PurSelecTM

 

 

PurSelecTM is a technology developed by APSIS for regiospecific and stereoselective alkylation and glycosylation for library synthesis of purine nucleoside analogues.

 

 

ntpLibraryTM

 

APSIS claims a technology for library synthesis of nucleoside analogue triphosphates.

 

 

Cas9-lgRNATM

 

 

APSIS develops oligonucleotide-protein gene cleaving complexes (Engineered CRISPR-Cas9-lgRNA) and delivery technologies targeting viral DNAs for curing latent and/or chronic viral infections.